Search research articles
Contact Us
Filters
Showing results (31-40 of 61) with videos related to
Page
of 7
Sort By:
Plos One
|
April 28, 2020
Optimal PD-L1-high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy
Magdalena Zajac, Jiabu Ye, Pralay Mukhopadhyay, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 8, 2019
Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study
Anne-Marie Boothman, Marietta Scott, Marianne Ratcliffe, et al.
Journal of the American College of Cardiology
|
August 18, 2004
Effects of gene delivery on collateral development in chronic hypoperfusion: diverse effects of angiopoietin-1 versus vascular endothelial growth factor
Yi Fu Zhou, Eugenio Stabile, Jill Walker, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
September 19, 2019
Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis
Moritz Widmaier, Tobias Wiestler, Jill Walker, et al.
Diagnostic Pathology
|
October 9, 2016
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma
Marlon C Rebelatto, Anita Midha, Amita Mistry, et al.
Patient Education and Counseling
|
October 15, 2021
Ask Rosa - The making of a digital genetic conversation tool, a chatbot, about hereditary breast and ovarian cancer
Elen Siglen, Hildegunn Høberg Vetti, Aslaug Beathe Forberg Lunde, et al.
Journal of Medicinal Chemistry
|
February 27, 2014
Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compound
Wieslaw M Kazmierski, Andrew Maynard, Maosheng Duan, et al.
Journal of Medicinal Chemistry
|
November 15, 2013
Imidazopyridazine hepatitis C virus polymerase inhibitors. Structure-activity relationship studies and the discovery of a novel, traceless prodrug mechanism
Martin Leivers, John F Miller, Stephanie A Chan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 11, 2009
Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer
N V Rajeshkumar, Aik Choon Tan, Elizabeth De Oliveira, et al.
Clinical Pharmacology in Drug Development
|
April 30, 2016
A randomized, double blind, dose escalation, first time in human study to assess the safety, tolerability, pharmacokinetics, and antiviral activity of single doses of GSK2485852 in chronically infected hepatitis C subjects
David A Wilfret, Jill Walker, Christian Voitenleitner, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 61) with videos related to
Sort By:
Page
of 7
Plos One
|
April 28, 2020
Optimal PD-L1-high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy
Magdalena Zajac, Jiabu Ye, Pralay Mukhopadhyay, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 8, 2019
Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study
Anne-Marie Boothman, Marietta Scott, Marianne Ratcliffe, et al.
Journal of the American College of Cardiology
|
August 18, 2004
Effects of gene delivery on collateral development in chronic hypoperfusion: diverse effects of angiopoietin-1 versus vascular endothelial growth factor
Yi Fu Zhou, Eugenio Stabile, Jill Walker, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
September 19, 2019
Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis
Moritz Widmaier, Tobias Wiestler, Jill Walker, et al.
Diagnostic Pathology
|
October 9, 2016
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma
Marlon C Rebelatto, Anita Midha, Amita Mistry, et al.
Patient Education and Counseling
|
October 15, 2021
Ask Rosa - The making of a digital genetic conversation tool, a chatbot, about hereditary breast and ovarian cancer
Elen Siglen, Hildegunn Høberg Vetti, Aslaug Beathe Forberg Lunde, et al.
Journal of Medicinal Chemistry
|
February 27, 2014
Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compound
Wieslaw M Kazmierski, Andrew Maynard, Maosheng Duan, et al.
Journal of Medicinal Chemistry
|
November 15, 2013
Imidazopyridazine hepatitis C virus polymerase inhibitors. Structure-activity relationship studies and the discovery of a novel, traceless prodrug mechanism
Martin Leivers, John F Miller, Stephanie A Chan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 11, 2009
Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer
N V Rajeshkumar, Aik Choon Tan, Elizabeth De Oliveira, et al.
Clinical Pharmacology in Drug Development
|
April 30, 2016
A randomized, double blind, dose escalation, first time in human study to assess the safety, tolerability, pharmacokinetics, and antiviral activity of single doses of GSK2485852 in chronically infected hepatitis C subjects
David A Wilfret, Jill Walker, Christian Voitenleitner, et al.
Page
of 7